BackTable Urology
Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo
Dr. Andrea Apolo
So I'm excited about the antibody drug conjugates in combination with checkpoint inhibitor trials. There's three large trials, and this is, of course, because of the amazing 302 data where we saw doubling of the overall survival in patients in the first-line treatment with metastatic bladder cancer.
0
💬
0
Comments
Log in to comment.
There are no comments yet.